Lundbeck has ended its bidding war with Alkermes to acquire Avadel Pharmaceuticals, saying that it will not increase its offer for the sleep disorder drug developer beyond the approximately $2.4 ...

Researchers say in future it may be possible to grow personalized organoids from patient’s own tissue, to test potential treatments in advance.

IBP-9414 will be the first live biotherapeutic product globally, according to officials at Infant Bacterial Therapeutics in Stockholm.

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.